Zurcher Kantonalbank Zurich Cantonalbank Purchases 13,833 Shares of Soleno Therapeutics, Inc. $SLNO

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Soleno Therapeutics, Inc. (NASDAQ:SLNO) by 191.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 21,075 shares of the company’s stock after acquiring an additional 13,833 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Soleno Therapeutics were worth $976,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new position in shares of Soleno Therapeutics in the 2nd quarter worth approximately $25,000. Danske Bank A S bought a new position in shares of Soleno Therapeutics in the 3rd quarter worth approximately $27,000. Aster Capital Management DIFC Ltd bought a new position in shares of Soleno Therapeutics in the 3rd quarter worth approximately $37,000. Quarry LP bought a new position in shares of Soleno Therapeutics in the 3rd quarter worth approximately $47,000. Finally, Quantbot Technologies LP bought a new position in shares of Soleno Therapeutics in the 3rd quarter worth approximately $67,000. Institutional investors own 97.42% of the company’s stock.

Wall Street Analysts Forecast Growth

SLNO has been the subject of several research reports. Zacks Research lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, February 3rd. Piper Sandler lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, April 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Soleno Therapeutics in a research report on Thursday, January 22nd. Wolfe Research lowered Soleno Therapeutics from an “outperform” rating to a “hold” rating in a research report on Tuesday, April 7th. Finally, Lifesci Capital lowered Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, April 6th. Three equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Soleno Therapeutics has an average rating of “Hold” and an average target price of $76.67.

Soleno Therapeutics Stock Performance

Shares of SLNO opened at $52.82 on Friday. The business’s fifty day simple moving average is $42.46 and its two-hundred day simple moving average is $46.89. The company has a current ratio of 5.80, a quick ratio of 5.55 and a debt-to-equity ratio of 0.11. Soleno Therapeutics, Inc. has a 12 month low of $29.43 and a 12 month high of $90.32. The company has a market cap of $2.73 billion, a price-to-earnings ratio of 229.66 and a beta of -2.81.

Soleno Therapeutics (NASDAQ:SLNO) last issued its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.64 by $0.16. The business had revenue of $91.73 million for the quarter, compared to analysts’ expectations of $88.55 million. Research analysts anticipate that Soleno Therapeutics, Inc. will post 3.67 earnings per share for the current fiscal year.

Soleno Therapeutics Profile

Soleno Therapeutics, Inc is a clinical?stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small?molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.